Velorum Therapeutics (YC W24)

About Velorum Therapeutics (YC W24)

The startup is a biotechnology research firm focused on treating hard-to-treat cancers by utilizing biologics that inhibit tumor growth and reprogram the tumor microenvironment. Their approach targets a pan-cancer metabolic vulnerability, providing drugs that effectively starve tumors in lung and breast cancers.

```xml <problem> Many cancers are difficult to treat due to their ability to evade the immune system and establish a microenvironment that supports tumor growth. Current therapies often fail to address the metabolic vulnerabilities that fuel cancer cell proliferation and resistance to treatment. </problem> <solution> This biotechnology company is developing biologic therapies designed to inhibit tumor growth and reprogram the tumor microenvironment, specifically targeting a pan-cancer metabolic vulnerability. Their approach aims to starve tumors by disrupting key metabolic pathways essential for cancer cell survival and proliferation. By targeting the tumor microenvironment, the therapies also seek to enhance the effectiveness of other cancer treatments and prevent recurrence. The company's research focuses on developing novel biologics that can effectively target and disrupt these metabolic processes, leading to improved outcomes for patients with hard-to-treat cancers. </solution> <features> - Biologic therapies targeting pan-cancer metabolic vulnerabilities. - Drugs designed to starve tumors by disrupting key metabolic pathways. - Reprogramming of the tumor microenvironment to enhance treatment efficacy. </features> <target_audience> The primary target audience includes patients with hard-to-treat cancers, oncologists, and researchers in the field of cancer biology. </target_audience> ```

What does Velorum Therapeutics (YC W24) do?

The startup is a biotechnology research firm focused on treating hard-to-treat cancers by utilizing biologics that inhibit tumor growth and reprogram the tumor microenvironment. Their approach targets a pan-cancer metabolic vulnerability, providing drugs that effectively starve tumors in lung and breast cancers.

Where is Velorum Therapeutics (YC W24) located?

Velorum Therapeutics (YC W24) is based in South San Francisco, United States.

How much funding has Velorum Therapeutics (YC W24) raised?

Velorum Therapeutics (YC W24) has raised 500000.

Location
South San Francisco, United States
Funding
500000
Employees
5 employees
Major Investors
Y Combinator, Eight Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

Velorum Therapeutics (YC W24)

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

The startup is a biotechnology research firm focused on treating hard-to-treat cancers by utilizing biologics that inhibit tumor growth and reprogram the tumor microenvironment. Their approach targets a pan-cancer metabolic vulnerability, providing drugs that effectively starve tumors in lung and breast cancers.

velorumtx.com500+
cb
Crunchbase
South San Francisco, United States

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator, Eight Capital

Team (5+)

No team information available.

Company Description

Problem

Many cancers are difficult to treat due to their ability to evade the immune system and establish a microenvironment that supports tumor growth. Current therapies often fail to address the metabolic vulnerabilities that fuel cancer cell proliferation and resistance to treatment.

Solution

This biotechnology company is developing biologic therapies designed to inhibit tumor growth and reprogram the tumor microenvironment, specifically targeting a pan-cancer metabolic vulnerability. Their approach aims to starve tumors by disrupting key metabolic pathways essential for cancer cell survival and proliferation. By targeting the tumor microenvironment, the therapies also seek to enhance the effectiveness of other cancer treatments and prevent recurrence. The company's research focuses on developing novel biologics that can effectively target and disrupt these metabolic processes, leading to improved outcomes for patients with hard-to-treat cancers.

Features

Biologic therapies targeting pan-cancer metabolic vulnerabilities.

Drugs designed to starve tumors by disrupting key metabolic pathways.

Reprogramming of the tumor microenvironment to enhance treatment efficacy.

Target Audience

The primary target audience includes patients with hard-to-treat cancers, oncologists, and researchers in the field of cancer biology.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.